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Toxin-antitoxin (TA) gene pairs have been identiﬁed in nearly all bacterial genomes sequenced to date and are thought to facilitate persistence and antibiotic tolerance. TA loci are classiﬁed into various types based upon the characteristics
of their antitoxins, with those in type II expressing proteic antitoxins. Many toxins
from type II modules are ribonucleases that maintain a PilT N-terminal (PIN) domain
containing conserved amino acids considered essential for activity. The vapBC
(virulence-associated protein) TA system is the largest subfamily in this class and has
been linked to pathogenesis of nontypeable Haemophilus inﬂuenzae (NTHi). In this
study, the crystal structure of the VapBC-1 complex from NTHi was determined to
2.20 Å resolution. Based on this structure, aspartate-to-asparagine and glutamate-toglutamine mutations of four conserved residues in the PIN domain of the VapC-1
toxin were constructed and the effects of the mutations on protein-protein interactions, growth of Escherichia coli, and pathogenesis ex vivo were tested. Finally, a
novel model system was designed and utilized that consists of an NTHi ΔvapBC-1
strain complemented in cis with the TA module containing a mutated or wild-type
toxin at an ectopic site on the chromosome. This enabled the analysis of the effect
of PIN domain toxin mutants in tandem with their wild-type antitoxin under the
control of the vapBC-1 native promoter and in single copy. This is the ﬁrst report of
a system facilitating the study of TA mutant operons in the background of NTHi during infections of primary human tissues ex vivo.

IMPORTANCE Herein the crystal structure of the VapBC-1 complex from nontype-

able Haemophilus inﬂuenzae (NTHi) is described. Our results show that some of the
mutations in the PIN domain of the VapC-1 toxin were associated with decreased
toxicity in E. coli, but the mutants retained the ability to homodimerize and to heterodimerize with the wild-type cognate antitoxin, VapB-1. A new system was designed and constructed to quantify the effects of these mutations on NTHi survival
during infections of primary human tissues ex vivo. Any mutation to a conserved
amino acid in the PIN domain signiﬁcantly decreased the number of survivors compared to that of the in cis wild-type toxin under the same conditions.
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oxin-antitoxin (TA) loci were ﬁrst identiﬁed on plasmids as modules that aided in
plasmid maintenance and stability by mediating the killing of plasmid-free cells and
thereby ensuring stable plasmid inheritance (1, 2). Following the advent of wholeJune 2019 Volume 201 Issue 12 e00026-19
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genome sequencing, TAs were found to be maintained in the chromosomes of numerous Gram-negative and Gram-positive bacterial genera as well as in the Archaea
(3–5). Chromosomally located TAs have been implicated as important metabolic regulators in many human pathogens, including Escherichia coli, nontypeable Haemophilus
inﬂuenzae (NTHi), Mycobacterium tuberculosis, and Staphylococcus aureus (6–9). Stressful
environmental conditions, such as nutrient limitation, heat, pH, and oxidative stress
from the host immune response or antibiotic therapy (10–13), initiate degradation of
the labile antitoxin via bacterial proteases such as Lon and ClpXP (14, 15). After the
antitoxin is degraded, the toxin is free to inhibit essential cellular processes, such as ATP
and protein synthesis, DNA replication, peptidoglycan synthesis, and cell division
(16–20), resulting in growth arrest and facilitating a persister state.
TA modules are operons typically organized with the antitoxin located directly
upstream of the toxin. Six different TA families have been identiﬁed and characterized
by the nature of the antitoxin. In type I and type III systems, the antitoxin is an RNA. The
type I antitoxin is antisense RNA that binds the toxin mRNA under normal cellular
conditions, inhibiting its translation (21). Following degradation of the type I antitoxin,
the toxin is translated and depolarizes the cell membrane, thereby inhibiting ATP
synthesis (21, 22). In the type III TA loci, the antitoxin is a pseudoknot RNA that binds
to the protein toxin and prevents it from cleaving RNA (23, 24). Type II, IV, V, and VI
systems all contain protein antitoxins. In type II systems, both the antitoxin and the
toxin are proteins that form a nontoxic complex upon translation (25). Many toxins of
the type II TA modules have been characterized as RNases (17, 26). Type IV systems are
unique in that the antitoxin inhibits toxin activity by interacting directly with the targets
of the toxin, which are cytoskeletal proteins necessary for proper cell division (20, 27).
The only type V TA locus described to date is ghoST, in which the antitoxin inhibits the
activity of the toxin by cleaving its mRNA (28). There is one identiﬁed type VI locus
currently, designated socAB. In this module, the antitoxin SocA does not inhibit the
activity of the SocB toxin directly but rather guides it to the protease ClpXP (29). When
SocB is not degraded by ClpXP, it binds to DnaN and inhibits DNA replication and
elongation (29). Free-living prokaryotes tend to have more TA loci than obligate
intracellular microorganisms, and pathogenic bacteria often have more TA loci than
their nonpathogenic relatives (30). Maintaining numerous TA loci in their genomes may
increase the ability of microorganisms to rapidly respond to stresses in their microenvironments, and there is growing interest in studying the contributions of these
systems to microbial pathogenesis and persistence.
Type II modules are currently the best characterized, and the vapBC (virulenceassociated protein) system is the largest subfamily in this class, with VapB being the
antitoxin and VapC the RNase toxin. The VapB antitoxin has two roles in the VapBC
system: a region near its C terminus binds to and neutralizes the toxin, while its N
terminus binds DNA and increases the TA complex stability in autoregulating transcription of its cognate operon (31). The VapC toxin contains a conserved PilT N-terminal
(PIN) (32) domain that is crucial for its activity. While it has been shown that some VapC
homologues are able to target speciﬁc RNA in bacterial cells (26, 33, 34), it is important
to note that a VapC toxin has not yet been cocrystallized with its speciﬁc RNA target
(31).
NTHi is a human-adapted bacterial commensal of the upper respiratory tract and a
leading cause of recurrent otitis media in the pediatric population (35). This organism
maintains two vapBC modules in its chromosome, designated vapBC-1 and vapBC-2. We
have previously shown that the vapBC-1 locus signiﬁcantly increases survival during
infection, both in vivo and ex vivo (7). Despite low primary sequence homology among
the VapC toxins from different microorganisms, the PIN domain is ubiquitous and
characterized by highly conserved acidic, polar, and hydrophobic residues in the active
site (31, 36). Based on the VapBC-1 crystal structure, we introduced directed mutations
to four PIN domain residues and evaluated the resulting mutant’s protein-protein
interactions, effects on the growth of E. coli, and ability to survive during infections of
primary human tissues ex vivo.
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FIG 1 Structure of the H. inﬂuenzae VapC-1 monomer subunit. (A) Colored by secondary structure with
␣-helices (green) and ␤-sheets (magenta). (B) Primary and secondary structural elements of VapC-1.
Conserved active-site residues are indicated by arrows.

RESULTS
Structural analysis of VapBC-1. Although VapBC structures from other organisms
have been determined (37), the structure of VapBC-1 from NTHi has not been reported.
Therefore, the crystal structure of VapBC-1 was determined from a polyhistidine-tagged
construct that allowed the VapB-1 antitoxin to be coexpressed with the VapC-1 toxin.
The primary sequences of the puriﬁed toxin and antitoxin used for crystallization are
shown in Fig. S1 in the supplemental material.
The overall structure of NTHi VapC-1 adopts an ␣-␤-␣ sandwich fold in which ﬁve
central ␤-strands are ﬂanked by two ␣-helical regions typically observed for PIN-like
domains (Fig. 1A). Subunits of VapC-1 form a dimer in which the hydrophobic surfaces
of helices ␣3 and ␣5 are positioned approximately 10 Å from one another (Fig. 2A). The
active-site residues D6, E43, D99, and E120, depicted as spheres in Fig. 2A, are
conserved among various VapC species and adopt a spatial arrangement similar to that
of previously determined structures (Fig. S2). The main network of hydrogen bonds is
formed between dimer subunits through residues Y81 in helix ␣5 and N97, N98, and
W101 of helix ␣6 (Fig. 2B). An additional hydrogen bond is present between E75 of
subunit B and Y41 in helix ␣3 of subunit A. The reciprocal interaction, E75 in subunit A
with Y41 of subunit B, is not observed, as the side chains are positioned 5 Å apart. Thus,
this hydrogen bond interaction is not likely a critical interaction between dimer
subunits. Similar to previously determined structures (38, 39), the VapC-1 dimer has an
interface area of 1,024 Å2 and a solvation free-energy gain from dimer formation (ΔGint)
June 2019 Volume 201 Issue 12 e00026-19
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of ⫺21.6 kcal/mol, and 13% of the accessible surface area is buried, as determined with
the Proteins, Interfaces, Structures and Assemblies program (PISA) (40). As noted above,
there is minimal hydrogen bonding between the dimer subunits and no salt bridge
interactions are present.
The VapC-1 dimer adopts an arrangement similar to that of structures from other
organisms (Fig. 3). Comparison of the NTHi VapC-1 dimer with homologous structures,
identiﬁed from a PDBeFold search (41), yielded root mean square (RMS) deviations
between C␣ atoms of 1.85 Å (251 residues, VapC D98N from Shigella ﬂexneri, PDB no.
5ECD) (42), 1.85 Å (253 residues, VapBC from S. ﬂexneri, PDB no. 3TND) (43) and 1.79 Å
(256 residues, VapBC from Rickettsia felis in complex with DNA, PDB no. 3ZVK) (44). The
main difference is observed in helix ␣2, which is moved further away from helix ␣1 in
the NTHi VapC-1 dimer, as noted in Fig. 3A. As shown below, this relative difference in
position of helices ␣1 and ␣2 is necessary to accommodate VapB-1 binding. Slightly
lower RMS deviations were observed when comparing single subunits, and superposition with VapC-1 (subunit A) yielded proteins with the following PDB identiﬁcation
numbers: 5ECD (subunit A, 1.48 Å, 126 residues), 3TND (subunit C, 1.37 Å, 129 residues),
and 3ZVK (subunit A, 1.54 Å, 131 residues). The main conformational differences occur
in the relative positions of helices ␣1 and ␣2, as was observed for superposition of the
dimers noted above.
The VapB-1 portion of the NTHi VapBC-1 complex could be modeled from residues
M1 to P72 (subunit C) and residues M1 to D69 (subunit D). The overall structure of
VapB-1 consists of a ribbon-helix-helix motif in which the four ␤-sheets of the N
terminus dimerize with another subunit to form a ␤-barrel type of architecture (Fig. 4).
As determined using PISA (40), extensive hydrogen bonding and salt bridge interacJune 2019 Volume 201 Issue 12 e00026-19

jb.asm.org 4

Downloaded from https://journals.asm.org/journal/jb on 18 November 2022 by 128.82.12.254.

FIG 2 Structure of the H. inﬂuenzae VapC-1 dimer showing subunits A and B in magenta and cyan,
respectively. (A) View along the 2-fold axis of the dimer. Helices that form the interacting surfaces
between subunits are indicated. Conserved active-site residues are rendered as spheres. Note that E120
(chain A) was partially disordered, so not all of the side chain atoms were modeled. (B) Hydrogen bond
interactions (dashed lines) between residues of the dimer.
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FIG 3 Comparison of the H. inﬂuenzae VapC-1 dimer (magenta/cyan) with the VapC dimer from
homologous structures. (A) VapC D98N (coral) from S. ﬂexneri (PDB no. 5ECD); (B) VapBC (gold) from S.
ﬂexneri (PDB no. 3TND); (C) VapBC (green) from R. felis in complex with DNA (DNA not shown) (PDB no.
3ZVK).

tions are present between the dimer subunits (27 and 11, respectively), forming an
interface area of 1,662 Å2 and a solvation free-energy gain of ⫺17.0 kcal/mol. Notably,
25% of the accessible surface area is buried to form the dimer interface. The C terminus
contains a long stretch of ﬂexible residues occupied by two ␣-helices that bind to the
VapC-1 toxin, forming a 1:1 interaction between VapB-1 and VapC-1 subunits. A similar
architecture is observed for other VapBC structures, such as VapBC from R. felis in
complex with DNA (PDB no. 3ZVK). Superposition yielded RMS deviations between C␣
atoms of 1.89 Å (90 residues). As shown in Fig. S3, the dimerization core regions are
quite similar. However, the VapC-1 binding region of the C terminus adopts a markedly
different orientation relative to the VapB-1 ␤-barrel dimer core. This is not too surprising, given that VapBC complexes often adopt various quaternary structural arrangements that produce higher-order oligomers (31).
June 2019 Volume 201 Issue 12 e00026-19
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FIG 4 Structure of the H. inﬂuenzae VapB-1 dimer showing subunits C (gold) and D (blue). Secondary
structure elements are annotated for subunit C. (A) Perpendicular view; (B) view along the ␤-barrel axis;
(C) primary and secondary structural elements of VapB-1.

A.

C.

VapC-1

FIG 5 Structure of VapBC-1 with VapB-1 subunits C/D (gold/blue) and VapC-1 subunits A/B (magenta/cyan).
(A) Asymmetric unit showing the positioning of the C-terminal tail of VapB-1 (subunit C) occupying the cleft
formed by ␣1 to ␣4 of VapC-1 (subunit A); (B) asymmetric unit with an extra VapB-1 dimer related by
crystallographic symmetry (VapB-1’); (C) same as that shown in panel B but rendered as a surface.
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Although the toxin-antitoxin form commonly observed consists of 1:1 interactions
between subunits, the quaternary arrangement resulting from the binding of NTHi
VapB-1 to VapC-1 in this structure appears to be unique. As shown in Fig. 5A, the
asymmetric unit consists of a VapB-1 and VapC-1 dimer in which the C-terminal helices of

Structural and Functional Studies of VapBC-1
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B.

VapB-1 (subunit C) occupy a cleft formed by ␣1 to ␣4 of VapC-1 (subunit A). Subunit B of
VapC-1 forms a similar interaction with VapB-1 (subunit D). However, this interaction is with
a VapB-1 molecule related by crystallographic symmetry (Fig. 5B) and creates tightly packed
pairs of VapB-1 and VapC-1 dimers (Fig. 5C). This arrangement results in a row of alternating
VapB-1 and VapC-1 dimers that propagate (21 screw) along the crystallographic c axis, as
shown in Fig. S4.
As noted above, the C-terminal tails of VapB-1 are positioned within a cleft formed
by ␣1 to ␣4 of a VapC-1 dimer. Speciﬁcally, the C-terminal tail spanning P41 to P72
(subunit C) and P41 to D69 (subunit D) of VapB-1 (Fig. 6A) position the ␣-helices within
a complementary cleft of VapC-1 subunits A and B, respectively (Fig. 6B). The binding
interface between VapB-1 and VapC-1 is 1,385 Å2 with a solvation free-energy gain of
⫺21.8 kcal/mol. The majority of the hydrogen bond and salt bridge interactions occur
at the C terminus of VapB-1, spanning residues A66 to L70 (Fig. 7). Notably, R67 of
VapB-1 interacts with E43 and D99 of VapC-1, which are conserved catalytic residues
along with D6 and E120, among various VapC species (45). Similar interactions were
observed for the S. ﬂexneri VapBC structure (PDB no. 3TND), suggesting a similar mode
of VapC-1 inhibition. Additional hydrogen bond interactions are observed between G55
and N52 of VapB-1 and N56 and N52 of VapC-1 (not shown).
In an effort to determine the oligomeric state of VapBC-1 in solution, a sample was
analyzed by size exclusion chromatography and SDS-PAGE. A peak was observed at an
elution volume of 13.70 ml, which corresponds to an approximate molecular weight of
100,786 Da (Fig. S5A, peak F). The calculated molecular weights of the VapB-1 and
VapC-1 dimers are 21,722 Da and 33,742 Da, respectively, and the molecular weight of
the two dimers of both the antitoxin and the toxin is 110,928 Da. Therefore, this peak
most likely arises from the T4A4 oligomer. Notably, this peak contains both VapB-1 and
VapC-1, as determined by SDS-PAGE (Fig. S5B). However, additional peaks were obJune 2019 Volume 201 Issue 12 e00026-19
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FIG 6 Binding of VapB-1 to VapC-1. (A) Zoomed-in view of Fig. 5B showing the binding of the C-terminal
tail of VapB-1 subunit C residues P41 to P72 (gold) and subunit D residues P41 to D69 (blue) bound to
the VapC-1 dimer; (B) electrostatic surface of VapC-1 subunit A showing the binding of the C-terminal
␣-helices of VapB-1 (P41 to P72, gold) positioned within the cleft formed by ␣1 to ␣4 of VapC-1.
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A66

i-81
served at larger elution volumes that correspond to species with molecular weights
lower than those of the VapB-1 and VapC-1 subunits. Surprisingly, each of these peaks
contains both VapB-1 and VapC-1, as observed by SDS-PAGE. It is possible that this
phenomenon arises from nonspeciﬁc interactions between the column matrix and the
protein complex, retarding its elution and resulting in both proteins appearing in each
peak fraction.
Protein-protein interactions in vivo. Proteins encoded by type II TA modules form
nontoxic heterocomplexes of the antitoxin and toxin homodimers under normal
growth conditions in vivo (37). In order to examine antitoxin and toxin homodimer
formation and heterodimerization, a bacterial LexA-based system (46) was employed.
The LexA repressor consists of two domains, a DNA-binding domain (DBD) and a
dimerization domain. The DBD can function as a transcriptional repressor only in
dimeric form. Other domains can be fused in-frame to the DBD and will restore the
repressor’s function only if they interact (47). If the fused proteins interact, the lacZ
reporter gene is repressed, reducing ␤-galactosidase activity, which is quantitated
biochemically as dimensionless Miller units (48). Strong protein-protein interactions
result in minimal ␤-galactosidase activity, whereas weak interactions result in signiﬁcant activity.
This system was applied to evaluate the ability of VapC-1 single and double mutants
to interact with wild-type (WT) VapB-1 antitoxin (heterodimerization) as well as with
themselves (homodimerization) in vivo. The homodimerization of the wild-type VapC-1
toxin was not evaluated due to its substantial toxicity when overexpressed in a
high-copy-number plasmid. Table 1 shows that the VapC-1 mutants retained the ability
to homodimerize with comparative strengths of interaction of E120Q ⬎ D6N ⬎ E43Q

TABLE 1 Homodimerization of VapC-1 mutantsa
Homodimerization of LexA DBD fusion in
SU101 (Miller units)
Construct
pSR658 (control)
VapC-1 D6N
VapC-1 D99N
VapC-1 D6N D99N
VapC-1 E43Q
VapC-1 E43Q D99N
VapC-1 E120Q

Avg
1,302.6
38.5
59.5
148.3
55.5
39.2
27.6

ⴞSD
78.2
12.9
9.4
24.8
9.8
2.2
8.4

aThe

homodimerization of the wild-type VapC-1 toxin was not evaluated due to its substantial toxicity when
overexpressed in high copy number.
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FIG 7 Hydrogen bond interactions between the C-terminal end of VapB-1 subunit C (gold) and VapC-1
subunit A (magenta).
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TABLE 2 Heterodimerization of VapC-1 mutants with the wild-type VapB-1 antitoxin
Heterodimerization of LexA DBD fusion in
SU202 (Miller units)
Construct
Control vector
VapC-1 D6N
VapC-1 D99N
VapC-1 D6N D99N
VapC-1 E43Q
VapC-1 E43Q D99N
VapC-1 E120Q
VapC-1 wild type

ⴞSD
130.0
11.5
30.6
6.0
18.9
5.5
11.6
6.4

Avg
1,813.4
37.9
360.5
56.0
202.2
113.3
167.3
190.4

D99N ⬎ E43Q ⬎ D99N ⬎ D6N D99N mutants. Mutant or wild-type VapC-1 toxins could
heterodimerize with wild-type VapB-1 at relative levels of D6N ⬎ D6N D99N ⬎ E43Q
D99N ⬎ E120Q ⬎ WT ⬎ E43Q ⬎ D99N mutants (Table 2).
VapC-1 activity in vivo. A growth recovery assay was used to evaluate VapC-1
activity in E. coli. Mutant or wild-type VapC-1 toxins were individually cloned under the
control of the PBAD promoter and induced with 3.3 mM (0.05%, wt/vol) arabinose (49).
The wild-type VapB-1 antitoxin was under the control of the Ptrc promoter, and its
expression was induced with 0.5 mM IPTG (isopropyl-␤-D-thiogalactopyranoside) (50).
Thus, VapC-1 and VapB-1 could be induced either independently or simultaneously
from compatible plasmids that are cotransformed and expressed in the same E. coli
strain, LMG 194. To initiate the assay, a culture in early growth phase was split and
treated with (i) medium only, (ii) arabinose only, (iii) IPTG only, or (iv) both arabinose
and IPTG. Typically, signiﬁcant growth arrest occurred at approximately 70 min after
wild-type VapC-1 was induced, but this was not observed if the antitoxin was expressed
alone (Fig. 8A, red and green symbols, respectively). If VapB-1 and VapC-1 were
coinduced, the antitoxin inhibited the toxin RNase activity, and growth was similar to
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FIG 8 E. coli growth recovery assays with inducible wild-type or mutant VapC-1 toxins. (A) Noninduced E. coli growth (measured by absorbance at 595 nm) or
growth following induction of wild-type (WT) VapC-1, VapB-1, or both wild-type VapC-1 and VapB-1. (B to G) Similar growth experiments were performed with
the VapC-1 D6N (B), D99N (C), D6N D99N (D), E43Q (E), E43Q D99N (F), and E120Q (G) mutants. All data are plotted as the mean ⫾ SD of the results of three
biological replicates in triplicate. Statistical comparisons of growth following wild-type or mutant VapC-1 inductions with that of the corresponding noninduced
controls were made using the repeated-measures ANOVA. The signiﬁcance of the results were as follows: VapC-1 WT, P ⬍ 0.0001 (A); D6N mutant, P ⫽ 0.21 (B);
D99N mutant, P ⫽ 0.0015 (C); D6N D99N mutant, P ⫽ 0.15 (D); E43Q mutant, P ⫽ 0.39 (E); E43Q D99N mutant, P ⫽ 0.28 (F); E120Q mutant, P ⫽ 0.017 (G).
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that of the noninduced control (Fig. 8A, purple and blue symbols, respectively). The
results of experiments with the VapC-1 mutants are presented in Fig. 8B to G. Significantly attenuated growth was observed upon induction of VapC-1 in strains with the
wild-type and D99N and E120Q mutant toxins (red symbols in Fig. 8A, C, and G,
respectively), compared to the growth observed when VapB-1 was coinduced (purple
diamonds). However, the VapC-1 D6N, D6N D99N, E43Q, and E43Q D99N mutants did
not cause signiﬁcant growth arrest when induced in vivo (Fig. 8B and D to F, red
symbols).
Construction of an in cis ectopic system to study TA modules. The growth
recovery assay in E. coli strain LMG 194 is a valuable tool to evaluate the effects of toxin
and antitoxin expression. However, the antitoxin and toxin proteins are cloned into
separate multicopy vectors to allow independent expression and are controlled by
artiﬁcial promoters. Therefore, the assay does not allow either expression via the native
transcriptional regulation of the locus or the characterization of a mutant locus in single
copy on the chromosome. To evaluate these aspects, a novel system was developed
that consisted of the native vapBC-1 promoter controlling an operon containing the
wild-type vapB-1 gene, followed by either the wild-type or each mutant vapC-1 gene
(Fig. 9). This system mimics the natural sequential arrangement and copy number of
the operon. The module is ﬂanked by homologous regions of the metE pseudogene
from NTHi strain 86-028NP (NTHI_RS09270; an authentic frameshift resulting in a
deletion of over 100 amino acids), which targets the reconstructed TA locus to a
chromosomal region that is not in use. Brieﬂy, fusions are ampliﬁed by PCR, used to
transform NTHi, and homologously recombined into the chromosome at the
NTHI_RS09270 pseudogene site in single copy. NTHi is an obligate human parasite with
natural deletions in many genes involving metabolism. Since it scavenges a number of
essential molecules from its host, this results in the requirement to supplement the
growth medium in vitro but not in vivo or ex vivo (51–53). The well-characterized
86-028NP ΔvapBC-1 strain (7) was chosen as the background to analyze each tandem
fusion to eliminate contributions by the wild-type vapBC-1 locus. This novel approach
is the most biologically relevant system currently available to study the effects of TA
locus mutants in the background of NTHi.
To ensure that the in cis mutant modules had no effect on the replication of strains,
the growth of the reconstructed wild type, the vapBC-1 mutants, and the parent strain
86-028NP ΔvapBC-1 was measured over 10 h. There were no signiﬁcant differences in
growth among the strains (data not shown), supporting the use of this model to
investigate variations in pathogenesis attributable to mutations in VapC-1.
Effect of VapC-1 mutations on survival of NTHi in primary human tissues. The
EpiAirway model (AIR 100 ABF; MatTek, Ashland, MA, USA), which consists of antibioticfree primary human respiratory epithelial tissue at the air-liquid interface, was used to
evaluate the impact of VapC-1 mutations on NTHi survival during infections. After
coculturing the in cis-complemented strains with EpiAirway tissues in antibiotic-free
medium for 48 h, the tissues were treated with 100 g/ml gentamicin for 90 min to kill
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FIG 9 NTHi delivery vector for single-copy in cis expression of cloned genes. This construct is targeted to NTHI_RS09270, the metE pseudogene in strain
86-028NP. The native vapBC-1 promoter controls either the wild-type vapBC-1 operon or an engineered operon consisting of the wild-type vapB-1 antitoxin and
one of the vapC-1 mutated toxins.
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any NTHi not internalized, as this antibiotic does not enter the tissues. The surviving
internalized bacteria were recovered, diluted, and plated for viable colony counts. This
experiment was performed with six tissues originating from at least two different
EpiAirway kits. The survival of all strains containing VapC-1 mutants was signiﬁcantly
reduced compared to that of the strain containing wild-type toxin (Fig. 10). The survival
of the parent strain, 86-028NP ΔvapBC-1, was also signiﬁcantly decreased, as previously
reported (7).
DISCUSSION
The VapC-1 toxin of NTHi is an efﬁcient and highly active RNase, and the vapBC-1
locus is crucial for survival during infection, both ex vivo in primary human tissues and
in vivo in the chinchilla model of acute otitis media (7). The PIN domain of VapC
homologues has been implicated in the binding and cleavage of RNA substrates (42),
and many acidic residues in this domain are highly conserved (45). Other studies have
evaluated various mutations to the PIN domain (54, 55), and we previously demonstrated that the VapC-1 D99N mutant had signiﬁcantly reduced RNase activity, while
retaining the ability to bind VapB-1 (56).
The NTHi VapBC-1 structure provides insight into heterodimeric interactions and
enables comparisons with VapBC complexes from other organisms. Overall, the
VapBC-1 homodimer subunits are similar to other reported VapB and VapC structures,
adopting similar protein-protein interactions with the VapB C-terminal helices occupying clefts within VapC dimers. The homodimer subunits in VapBC complexes often form
higher-order oligomers, such as heterotetramers, heterohexamers, and heteroctamers
(31). Interestingly, the VapBC-1 complex does not adopt any of these higher-order
quaternary structures but instead forms a unique linear array of alternating VapB and
VapC dimers. It should be noted that the VapB construct used for crystallization
contains 18 additional residues at the N terminus from the cloning vector pET24b,
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FIG 10 Number of viable CFU/milliliter of NTHi in cis-complemented mutants or the wild-type
operon in primary human tissues at the air-liquid interface. EpiAirway tissues were infected at
⬃1.0 ⫻ 104 CFU per insert with either the 86-028NP ⌬vapBC-1 deletion strain, the 86-028NP
⌬vapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (wild-type) strain, the 86-028NP ⌬vapBC-1
NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (D6N) strain, the 86-028NP ⌬vapBC-1 NTHI_RS09270::PvapBC-1::
vapB-1vapC-1 (D99N) strain, the 86-028NP ⌬vapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (D6N
D99N) strain, the 86-028NP ⌬vapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E43Q) strain, the 86028NP ⌬vapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E43Q D99N) strain, the 86-028NP ⌬vapBC-1
NTHI_RS09270::PvapBC-1::vapB-1vapC-1 (E120Q) strain, or the 86-028NP ⌬vapBC-1 parent strain. At
48 h after infection, gentamicin-resistant bacteria were harvested for colony counts. Data are
expressed as the mean ⫾ SD (n ⫽ 6). All in cis mutants and the parent strain were signiﬁcantly
attenuated for survival compared to the strain carrying the wild-type VapC-1 in cis. An asterisk
denotes a P of ⱕ0.05.
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which were mostly disordered. Therefore, it is unclear if this unique quaternary structure arrangement is an artifact resulting from these additional residues.
Based on the crystal structure of VapBC-1, two highly conserved aspartate residues
and two glutamate residues in the toxin PIN domain were mutated to their beta-amino
derivatives, asparagine and glutamine. Analyses of these mutant constructs indicated
decreased RNase activity in vivo measured by growth recovery assays and decreased
survival during ex vivo infections of primary human tissues compared to that of the
wild-type toxin when expressed in the background of NTHi using a novel single-copy
in cis system. We also found that the effects of these mutations were not necessarily
additive, since although a VapC-1 D99N mutant was signiﬁcantly attenuated when
overexpressed in E. coli growth recovery assays, a D6N D99N double mutant was not.
Interestingly, all VapC-1 mutants were able to strongly homodimerize as well as to bind
wild-type VapB-1, suggesting that the module’s quaternary structure is somewhat
decoupled from the enzymatic activity of the toxin.
The results reported here support the notion that VapBC-1 (and TA modules in
general) have evolved a number of mechanisms to maintain their activity and that their
presence confers a signiﬁcant advantage to the microorganism. Many studies have
linked TA modules to the survival of bacterial pathogens in host tissues (7, 56–60).
Achieving and maintaining persistence during an infection is central for both successfully evading the immune response and for nonspeciﬁc antibiotic tolerance, leading to
a pathogen’s survival of clinical therapy. This characteristic can substantially contribute
to recurrent or chronic infections and implicates TA modules as therapeutic targets.
Indeed, when we tested the effects of the toxin mutations on NTHi survival inside
primary human respiratory tissues ex vivo, we found that any perturbation of the acidic
residues in the conserved PIN domain negatively affected survival in comparison to the
wild-type toxin under the same conditions. Our data suggest that targeting any of
these individual residues in the toxin could potentially result in a signiﬁcant decrease
in survival of NTHi during infection and imply that small-molecule inhibitors could be
most effective in this approach.

Bacterial strains and culture conditions. The bacterial strains and plasmids used in these studies
are listed in Table S1 in the supplemental material. E. coli strains were grown in LB broth or agar with or
without 100 g/ml ampicillin, 250 g/ml erythromycin, 20 g/ml chloramphenicol, 30 g/ml of kanamycin, or 12 g/ml tetracycline, as required. NTHi strains were grown in brain heart infusion broth or agar
supplemented with 10 g/ml heme-histidine and 10 g/ml ␤-NAD (sBHI) or on chocolate agar with
5 U/ml bacitracin. NTHi was routinely cultured at 37°C with 5% CO2. To construct the ectopic strains,
transformants were selected on chocolate agar plates with 5 g/ml erythromycin, and single colonies
were passaged for 3 days on selection plates before being conﬁrmed by DNA sequencing of PCRampliﬁed puriﬁed genomic DNA.
Site-directed mutagenesis of VapC-1. VapC-1 D6N and D99N mutants cloned in tandem with a
wild-type VapB-1 in the vector pET24b (Millipore Sigma, Burlington, MA) were previously described (61).
These constructs were used as the templates for plasmid expression sets. Synthetic constructs of VapC-1
with E43Q, E120Q, and E43Q D99N mutations were generated in tandem with wild-type VapB-1 by
Euroﬁns (Euroﬁns Genomics, Louisville, KY). The VapC-1 D6N D99N construct, also in tandem with the
wild-type VapB-1, was produced by GenScript (Piscataway, NJ). Each construct was conﬁrmed by DNA
sequencing (Euroﬁns Genomics, Louisville, KY) following subcloning into the vectors listed in Table S1.
Puriﬁcation of VapC-1 for crystallization studies. To overexpress VapBC-1 for puriﬁcation, pDD686
in BL21(DE3) (17) was grown to logarithmic phase at 37°C with shaking, induced for 18 h with 1 mM IPTG
at 26°C, and harvested at 2,500 ⫻ g into pellets from 25-ml aliquots. After one freeze-thaw cycle, VapBC-1
was isolated in accordance with the MagneHis protein puriﬁcation system (Promega, Madison, WI) with
the following exceptions: the lysis solution was 1⫻ BugBuster protein extraction reagent (Millipore
Sigma, Burlington, MA) with 100 mM HEPES (pH 7.2), 300 mM NaCl, 1⫻ ProteCEASE-50 (EDTA free), and
2 l/ml RNase-free DNase (Thermo Fisher Scientiﬁc, Waltham, MA); the wash buffer contained 100 mM
HEPES (pH 7.2), 300 mM NaCl, and 20 mM imidazole; and the elution buffer contained 100 mM HEPES (pH
7.2), 300 mM NaCl, and 500 mM imidazole. One microgram of puriﬁed VapBC-1 was separated on a Bolt
precast 4 to 12% polyacrylamide gel and analyzed via Western blotting using the iBlot and iBind system
(Thermo Fisher Scientiﬁc, Waltham, MA). The nitrocellulose blot was probed with a monoclonal anti-His
tag primary antibody (THE anti-His; GenScript, Piscataway, NJ), goat anti-mouse IgG– horseradish peroxidase (HRP) secondary antibody (GenScript, Piscataway, NJ), detected with SuperSignal West Dura chemiluminescence substrate (Thermo Fisher Scientiﬁc, Waltham, MA) and imaged on a UVP BioSpectrum 815 system
(UVP LLC, Upland, CA).
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Crystallization and data collection. A puriﬁed preparation of the NTHi VapBC-1 protein complex
was concentrated to 20 mg/ml in 20 mM NaCl, 10 mM HEPES (pH 7.2) for crystallization screening. All
crystallization experiments were set up using an NT8 drop setting robot (Formulatrix, Inc.) and UVXPO
MRC (Molecular Dimensions) sitting drop vapor diffusion plates at 18°C. One hundred nanoliters of
protein and 100 nl of crystallization solution were dispensed and equilibrated against 50 l of the latter.
Crystals approximately 100 m long that displayed a needle morphology (Fig. S6) were observed within
1 week from the Proplex screen (Molecular Dimensions) condition C3 (20% [wt/vol] PEG 4000, 100 mM
sodium acetate [pH 5.0], 200 mM ammonium acetate). A cryoprotectant solution composed of 80%
crystallization solution and 20% (vol/vol) PEG 200 was dispensed (2 l) onto the drop, and crystals were
harvested with a cryoloop immediately and stored in liquid nitrogen. X-ray diffraction data were
collected at the Advanced Photon Source beamline 17-ID using a Dectris Pilatus 6 M pixel array detector.
Structure solution and reﬁnement. Intensities were integrated using XDS (62, 63) via Autoproc (64),
and the Laue class analysis and data scaling, using two data sets to increase the multiplicity, were
performed with Aimless (65), which indicated that the crystals belong to the mmm Laue class. Structure
solution was conducted by molecular replacement with Morda (66) to place a VapC-1 dimer using
Shigella ﬂexneri VapC (PDB no. 5ECD) as the template, and the top solution was obtained in the space
group P212121. The VapC-1 coordinates from Morda were input as a ﬁxed solution into Phaser (67), and
a VapB monomer from the Rickettsia felis VapBC structure (PDB no. 3ZVK) was used as a search model.
The ﬁnal solution from Phaser consisted of a VapB-1 and VapC-1 dimer in the asymmetric unit, and the
model was improved by automated building with Arp/wARP (68). Further reﬁnement and manual model
building were conducted with Phenix (69) and Coot (70), respectively. Disordered side chains were
truncated to the point at which electron density could be observed. Structure validation was conducted
with Molprobity (71), and ﬁgures were prepared using the CCP4MG package (72). Structure superposition
was carried out with GESAMT (73). Crystallographic data are provided in Table 3.
Size exclusion chromatography. A 0.5-ml sample (5.8 mg/ml) of the coexpressed and puriﬁed
VapBC-1 construct was loaded onto a Superdex 200 10/300 GL column (GE Healthcare) equilibrated with
200 mM NaCl, 50 mM HEPES (pH 7.2). The sample was applied at a ﬂow rate of 0.5 ml using an AKTA pure
fast protein liquid chromatograph, and 1-ml fractions were collected. Chromatography data were
analyzed using the Unicorn 7 software package (GE Healthcare). The column was calibrated using protein
standard mixture containing thyroglobulin (670,000 Da), gamma globulin (158,000 Da), ovalbumin
(44,000 Da), myoglobin (17,000 Da), and vitamin B12 (1,350 Da). The molecular weights of the VapBC-1
peak fractions were estimated relative to the least-squares ﬁt of the calibration standards.
Cloning and protein-protein interactions of VapC-1 mutants. The VapC-1 D99N, E43Q, E43Q
D99N, and E120Q mutants were cloned by amplifying the vapC-1 D99N gene from pDD758, the vapC-1
E43Q gene from pDD1165, the vapC-1 E43Q D99N gene from pDD1196, or the vapC-1 E120Q gene from
pDD1166 using high-ﬁdelity Phusion Flash DNA polymerase (Thermo Fisher Scientiﬁc, Waltham, MA,
USA) and the primers 322LexFor and 322LexRev. The PCR products, pSR658, and pSR659 were digested
with SacI and KpnI prior to ligation, resulting in pDD1120, pDD1123, pDD1170, pDD1178, pDD1199,
pDD1200, pDD1177, and pDD1179. VapC-1 D6N and D6N D99N were cloned by amplifying the vapC-1
D6N gene from pDD757 and the vapC-1 D6N D99N gene from pDD1118, using high-ﬁdelity Phusion
Flash DNA Polymerase with pETD6NC1SacFor and 322LexRev primers. The PCR products, pSR660, and
pSR661 were digested with SacI and KpnI prior to ligation, resulting in pDD1125, pDD1126, pDD1129,
and pDD1128. The wild-type VapC-1 toxin was cloned into pSR659 with the above-described method
from NTHi strain 86-028NP genomic DNA (pDD1150). All clones were conﬁrmed by DNA sequencing. The
pSR659 or pSR661 constructs were cotransformed with pDD866 into SU202 to perform heterodimerization assays. The pSR658 or pSR660 constructs were individually transformed into SU101 for homodimerization assays.
Expression of the LexA fusions was induced by IPTG, and if the fusion proteins interacted, a
competent repressor that could bind the operator site and decrease transcription of the lacZ reporter
gene was formed in the reporter strain. This resulted in a measurable decrease in ␤-galactosidase activity
compared to a strain carrying the control unfused vectors. However, because ␤-galactosidase is a
long-lived enzyme, our reporter strains were grown overnight in the presence of 1 mM IPTG so that any
enzyme expressed prior to the LexA chimera induction was degraded. This strategy results in a more
reliable and accurate quantiﬁcation of homodimerization and heterodimerization. Following overnight
incubation on LB agar plates with 1 mM IPTG and appropriate antibiotics, reporter strains carrying the
control vectors (pSR658 and pSR659 or pSR660 and pSR661) (47) or the LexA DBD fusions were
inoculated and grown to an optical density at 600 nm (OD600) of ⬃0.5 in LB broth with 1 mM IPTG and
appropriate antibiotics. Protein-protein interactions were quantiﬁed by ␤-galactosidase activity assays
and compared to the activity of the reporter strain carrying the unfused vectors, which has the highest
activity due to the lack of repressor formation. The algorithm for quantifying ␤-galactosidase activity was
as follows: [OD420 – (1.75 ⫻ OD550)/(t ⫻ v ⫻ OD600)] ⫻ 1,000, where t is time of reaction development
in minutes and v is volume of sample in milliliters (48). This equation allows for the normalization of
different culture densities for comparison purposes.
Cloning and growth-recovery assays with VapC-1. To clone wild-type and mutant VapC-1 genes
for the growth recovery assays, the wild-type vapC-1 gene was ampliﬁed from NTHi strain 86-028NP
genomic DNA, the vapC-1 D6N gene was ampliﬁed from pDD757, the vapC-1 D99N gene was ampliﬁed
from pDD758, the vapC-1 D6N D99N gene was ampliﬁed from pDD1118, the vapC-1 E43Q gene was
ampliﬁed from pDD1165, the vapC-1 E43Q D99N gene was ampliﬁed from a synthetic gene produced by
Euroﬁns, and the vapC-1 E120Q gene was ampliﬁed from pDD1166 using high-ﬁdelity Phusion Flash DNA
polymerase with pBAD86C1SacFor and 322Rev primers. The PCR products and pBAD33 were digested
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TABLE 3 Crystallographic data for VapBC-1
Parameter
Data collection statistics
Unit cell parameters (Å, °)
Space group
Resolution (Å)a
Wavelength (Å)
Temp (K)
No. of observed reﬂections
No. of unique reﬂections
⬍l/(l)⬎a
Completeness (1%)a
Multiplicitya
Rmerge (%)a,b
Rmeas (%)a,d
Rpim (%)a,d
CC1/2a,e

a ⫽ 43.88, b ⫽ 57.32, c ⫽ 175.75
P212121
48.01–2.20 (2.28–2.20)
1.0000
100
303,859
23,388
10.9 (2.1)
100 (100)
13.0 (13.7)
16.8 (161.3)
17.5 (167.7)
4.9 (45.2)
0.998 (0.784)

Reﬁnement statistics
Resolution (Å)a
No. of reﬂections (working/test)a
Rfactor/Rfree (%)a,c
No. of atoms (VapB-1/VapC-1/water)

48.01–2.20
22,146/1,166
18.6/23.4
1,085/2,103/58

Model quality
RMS deviations
Bond length (Å)
Bond angle (°)
Avg B-factor (Å2)
All atoms
VapB-1
VapC-1
Water
Coordinate error (maximum likelihood) (Å)
Ramachandran plot
Most favored (%)
Additionally allowed (%)

Value(s) for VapBC-1

0.009
0.981
43.5
48.0
41.3
41.8
0.24
96.8
3.0

aValues

in parenthesis are for the highest-resolution shell.
⫽ ⌺hkl⌺i |Ii(hkl) – ⬍I(hkl)⬎|/⌺hkl⌺i Ii(hkl), where Ii(hkl) is the intensity measured for the ith reﬂection
and ⬍I(hkl)⬎ is the average intensity of all reﬂections with indices hkl.
cR
factor ⫽ ⌺hkl Fobs (hkl) | ⫺ |Fcalc (hkl)/⌺hkl |Fobs (hkl)|; Rfree is calculated in an identical manner using 5% of
randomly selected reﬂections that were not included in the reﬁnement.
dR
meas, redundancy-independent (multiplicity-weighted) Rmerge (65, 77); Rpim, precision-indicating
(multiplicity-weighted) Rmerge (78, 79).
eCC
1/2 is the correlation coefﬁcient of the mean intensities between two random half-sets of data (80, 81).
merge

with SacI and HindIII prior to ligation, resulting in pDD946, pDD1132, pDD1133, pDD1119, pDD1175,
pDD1194, and pDD1174. The forward primer was designed to include the putative Shine-Dalgarno
sequence for VapC-1. The vapB-1 gene was ampliﬁed from 86-028NP genomic DNA using high-ﬁdelity
Phusion Flash DNA polymerase with 321LexFor and 321LexRev primers. After digestion with SacI and
KpnI the PCR fragment was ligated into pTrcHisA, resulting in pDD935. All clones were veriﬁed by DNA
sequencing. Wild-type vapC-1 and each of the six mutants were cotransformed with pDD935 into E. coli
strain LMG 194.
To perform the growth recovery assays, strains were grown at 37°C to early log phase (OD600, ⬃0.2
to 0.3) in LB broth with 20 g/ml chloramphenicol and 100 g/ml ampicillin before being diluted in a
1:1 (vol/vol) ratio to a ﬁnal volume of 150 l of medium in a 96-well Falcon polystyrene microplate
(Corning, Corning, NY) containing LB broth with 20 g/ml chloramphenicol and 100 g/ml ampicillin,
with or without 1 mM IPTG, 6.6 mM (0.1%, wt/vol) arabinose, or both. The ﬁnal induction concentrations
were 0.5 mM IPTG and 3.3 mM (0.05%, wt/vol) arabinose. The plate was covered with a gas-permeable
membrane, loaded into a Multiskan FC incubating plate reader (Thermo Fisher Scientiﬁc, Waltham, MA),
and incubated at 37°C with a shaking protocol of 5 s on and 5 s off, with measurements taken every 10
min at OD595 for 190 min. Each assay included three biological replicates with three technical replicates.
Construction of the in cis delivery system and reconstituted NTHi strains. Based on a previously
published ectopic delivery vector in NTHi (74), the metE pseudogene in the chromosome of strain
86-028NP (NTHI_RS09270) was targeted as the site for gene delivery and single-copy expression in cis.
The delivery vector was constructed by amplifying 843 bp of the 5= end of NTHI_RS09270 from 86-028NP
genomic DNA using high-ﬁdelity Phusion Flash DNA polymerase with 2009-1SacFor and 2009-1XbaRev
primers and ligating the product into pBluescript SK⫹ digested with SacI and XbaI, resulting in pDD1058.
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The second homologous region of 767 bp of the 3= end of NTHI_RS09270 was ampliﬁed from 86-028NP
genomic DNA using high-ﬁdelity Phusion Flash DNA polymerase with 2009-2XhoFor and 2009-2KpnRev
primers and ligated into pDD1058 cut with XhoI and KpnI, resulting in pDD1063. The last step was
amplifying an erythromycin resistance cassette from pEJ18 (75) with PermCSpeFor and ErmCSpeRev
primers and ligating into pDD1063 cut with SpeI, resulting in the delivery vector, pDD1140. The native
vapBC-1 promoter from 86-028NP was cloned into the multiple cloning site of the delivery vector using
the primers BC1PromBamFor and BC1PromNdeRev. The reverse primer contains an engineered NdeI site
(CATATG) in which the ATG of the restriction site (underlined) serves as the start codon for the fused
vapBC-1 genes. This allowed us to clone all constructs with their native transcriptional regulation and
organization. The vapBC-1 promoter was ligated to pDD1140 cut with BamHI and EcoRV, resulting in
pDD1155. Because the vapC-1 mutants are in tandem with the wild-type vapB-1 gene, each was cloned
into pDD1155 for delivery into the 86-028NP chromosome. The vapBC-1 D6N locus was ampliﬁed from
pDD757, vapBC-1 D99N was ampliﬁed from pDD758, vapBC-1 D6N D99N was ampliﬁed from pDD1118,
vapBC-1 E43Q was ampliﬁed from pDD1165, vapBC-1 E43Q D99N was ampliﬁed from a synthetic gene
produced by Euroﬁns, vapBC-1 E120Q was ampliﬁed from pDD1166, and wild-type vapBC-1 was ampliﬁed
from pDD686 using high-ﬁdelity Phusion Flash DNA polymerase with 86B1NdeFor and 322Rev primers.
Each amplicon was ligated to pDD1155 digested with NdeI and HindIII, resulting in pDD1159, pDD1160,
pDD1161, pDD1167, pDD1204, pDD1168, and pDD1169. This resulted in vapBC-1 with the desired
mutations in vapC-1 under the control of its native promoter (Fig. 9).
The strains of NTHi 86-028NP ΔvapBC-1 NTHI_RS09270::PvapBC-1::vapB-1vapC-1 with wild-type vapC-1
and the six mutants were constructed by homologous recombination into the chromosome of 86-028NP
ΔvapBC-1 by PCR products containing both the ﬂanking regions of NTHI_RS09270 and each promotertandem gene clone using MIV transformation (53). After selection on chocolate agar with 5 g/ml
erythromycin, a single colony of each transformant was passaged three times on antibiotic-containing
plates. DNA sequencing of PCR-ampliﬁed genomic DNA preparations conﬁrmed each correct strain.
To ensure that the in cis fusions did not affect the growth dynamics of NTHi, strains were grown to
early log phase (OD600, ⬃0.2 to 0.3) in sBHI broth before dilution into a 96-well Falcon polystyrene
microplate, and absorbance was measured by following the same protocol as that of the growth recovery
assays over the course of 10 h. Each growth assay included three biological replicates with three technical
replicates.
NTHi infections of primary human tissues. EpiAirway tissues (AIR-100-ABF; MatTek, Ashland, MA)
were maintained, inoculated, and harvested as previously described (76), with the following exception:
inserts were inoculated with approximately 25 l of a 1.0 ⫻ 104 CFU/ml bacterial suspension of the
desired strain. Inserts were cocultured with the parent, wild-type, or mutant strains for 48 h before
harvesting and quantiﬁcation by counting viable colonies from a plated dilution series on chocolate agar
plates.
Statistical analyses. Differences between means were determined using Student’s t test. Differences
among multiple-group treatments were determined by the repeated-measures analysis of variance
(ANOVA) or two-way ANOVA as appropriate using Prism 8.0.1 (GraphPad Software, La Jolla, CA). A P value
of ⱕ0.05 was considered statistically signiﬁcant.
Data availability. Coordinates and structure factors were deposited in the worldwide Protein Data
Bank (wwPDB) under accession code 6NKL.
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